187 related articles for article (PubMed ID: 19309570)
1. A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project.
Vena GA; Galluccio A; De Simone C; Mastrandrea V; Buquicchio R; La Greca S; Dattola S; Puglisi Guerra A; Donato L; Cantoresi F; De Pità O; Pezza M; D Agostino M; Vernaci R; Miracapillo A; Valenti G; Cassano N
Int J Immunopathol Pharmacol; 2009; 22(1):227-33. PubMed ID: 19309570
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.
Leonardi C; Sobell JM; Crowley JJ; Mrowietz U; Bao Y; Mulani PM; Gu Y; Okun MM
Br J Dermatol; 2012 Sep; 167(3):658-67. PubMed ID: 22564148
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study.
Asahina A; Nakagawa H; Etoh T; Ohtsuki M;
J Dermatol; 2010 Apr; 37(4):299-310. PubMed ID: 20507398
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation.
Martyn-Simmons CL; Green L; Ash G; Groves RW; Smith CH; Barker JN
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1394-7. PubMed ID: 19573024
[TBL] [Abstract][Full Text] [Related]
6. Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis.
Gniadecki R; Leonardi CL; Gordon KB; Gu Y; Geng Z; Nader A; Teixeira HD
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1297-1304. PubMed ID: 29524255
[TBL] [Abstract][Full Text] [Related]
7. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
8. Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data.
Cassano N; Galluccio A; De Simone C; Loconsole F; Massimino SD; Plumari A; Dattola S; Puglisi Guerra A; Donato L; Cantoresi F; De Pita O; Fenizi G; Altamura V; Congedo M; Pellicano R; Vena GA
J Biol Regul Homeost Agents; 2008; 22(4):233-7. PubMed ID: 19036225
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.
Gordon K; Papp K; Poulin Y; Gu Y; Rozzo S; Sasso EH
J Am Acad Dermatol; 2012 Feb; 66(2):241-51. PubMed ID: 21752491
[TBL] [Abstract][Full Text] [Related]
11. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
Menter A; Tyring SK; Gordon K; Kimball AB; Leonardi CL; Langley RG; Strober BE; Kaul M; Gu Y; Okun M; Papp K
J Am Acad Dermatol; 2008 Jan; 58(1):106-15. PubMed ID: 17936411
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study.
Papp K; Ho V; Teixeira HD; Guerette B; Chen K; Lynde C
J Eur Acad Dermatol Venereol; 2012 Aug; 26(8):1007-13. PubMed ID: 22023702
[TBL] [Abstract][Full Text] [Related]
14. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital.
Noda S; Mizuno K; Adachi M
J Dermatol; 2012 Mar; 39(3):265-8. PubMed ID: 22126280
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis.
Bagel J
J Drugs Dermatol; 2011 Apr; 10(4):366-71. PubMed ID: 21455546
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study.
Papp K; Menter A; Poulin Y; Gu Y; Sasso EH
J Eur Acad Dermatol Venereol; 2013 May; 27(5):634-42. PubMed ID: 22429586
[TBL] [Abstract][Full Text] [Related]
17. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P
J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of biologic therapies for plaque psoriasis.
Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.
Ryan C; Kirby B; Collins P; Rogers S
Clin Exp Dermatol; 2009 Oct; 34(7):784-8. PubMed ID: 19438535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
